|Day Low/High||183.37 / 186.28|
|52 Wk Low/High||147.60 / 270.63|
Shire posted full-year profits that were largely in-line with analysts' forecasts and said it could see double-digit percentage growth in 2017 earnings per share.
Shire presentations at EAHAD 2017 underscore the company's leadership in improving global standards of care
The charts of these and two other big stocks are flashing warning signs at investors.
The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.
U.S. stock futures and shares in London and Asia fall Thursday after Donald Trump offers few details on his policies during his first press conference since winning the U.S. election.
European health care and pharmaceutical company shares were hit hard Thursday after President-elect Donald Trump accused some firms of 'getting away with murder' in his Wednesday press conference.
U.S. Patent Office allows Mylan to go after half a dozen patents tied to Allergan's dry eye franchise Restasis.
The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.
The Swiss biotech was last year reported to be a target of Shire.
Company to expand into 500 Kendall Street and create a 550,000-square-foot campus focused on rare diseases and highly specialized conditions
Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?
Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.
The threat of a government clampdown on drug prices is off the table with Clinton's defeat, while wider support for defensive stocks helped push pharmaceuticals higher.
Stocks slip on Tuesday in a weaker start to November as uncertainty over the upcoming presidential election weighs on Wall Street.